Abstract Purpose: The COMPARE study examined facility costs of sonography-guided transcervical fibroid ablation (TFA) using the Sonata System, hysterectomy, and myomectomy for the treatment of symptomatic uterine fibroids. Design and methodology: A facility-perspective cost analysis of hospital charge…
Starting a health plan is difficult and success is certainly not guaranteed. Of three 2014 start-up health plans in New York City, Health Republic closed in 2015 and CareConnect closed on New Year’s Eve 2017. Only Oscar remains, and it racked up cumulative losses of $235 million from 2014 to 2016.
Real-world data challenge assumptions regarding typical factor usage and expenditures associated with product switching in patients with hemophilia A. There were higher expenditures over two years on hemophilia A patients using extended half-life (EHL) versus standard half-life (SHL) products.
Asthma is a common chronic respiratory disease affecting nearly 8% of the U.S. population. Fractional exhaled nitric oxide (FeNO) is a noninvasive biomarker for T2-driven (i.e., allergic) airway inflammation that could be used to improve diagnosis, optimize inhaled corticosteroid dosing, and monitor adherence.
Current asthma guidelines combine treatment, follow-up, and re-evaluation to manage asthma control, reduce impairment, and decrease risk of morbidity in patients. Analysis reveals that FeNO monitoring to guide asthma management is cost effective, increasing quality-adjusted life years while decreasing costs associated with asthma management.
An age/sex/gene expression score helped to identify patients with low current likelihood of obstructive coronary artery disease. These patients had lower costs of CAD care during one year of follow-up. Early reductions in cardiac referrals at 45 days among these patients persisted for one year.
ACOs need to provide comprehensive care management across a spectrum of provider specialties. To do this, they need a framework for evaluating potential partners that will help risk-bearing providers establish the partnerships that will enable them to achieve their goals.
As expected, pharmacy costs increased with the introduction of this new treatment in a market dominated by over-the-counter and generic treatments. On the other hand, outpatient GI-related and irritable bowel disease health care resource use and costs substantially decreased among commercial and Medicare patients following linaclotide treatment initiation.